Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’s pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego.

Neurimmune Holding AG is a private company headquartered in Schlieren, Switzerland, with domestic subsidiaries, that manufactures pharmaceutical products. The firm was founded in 2006.\nThe company says this about itself: Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, dementia with Lewy bodies and ATTR cardiomyopathy. Neurimmune discovered aducanumab, a human monoclonal antibody that removes amyloid beta from brains of patients with Alzheimer's disease, and licensed it to Biogen. With its RTM™ technology, Neurimmune also discovered the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for ATTR cardiomyopathy, programs being currently evaluated in clinical trials. Neurimmune has three additional antibody programs in preclinical development, and has recently expanded the spectrum of its treatment modalities by adding a small molecule program and programs involving vectorized expression of human antibody genes.

SOM Biotech is a drug innovation company based on a pioneering AI-based drug discovery technology – SOM AI PRO -, that has built a robust pipeline focused mainly on Orphan CNS products with very high unmet need and blockbuster potential. SOM AI PRO has been validated with 2 successful Phase 2 trials (TTR Amyloidosis, Chorea in Huntington disease), and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Pfizer Inc. (NYSE: PFE, /ˈfaɪzər/) is an American multinational pharmaceutical corporation headquartered in New York City was founded in 1849, based in New York City and was listed on New York Stock Exchange. It is one of the world's largest pharmaceutical companies. It is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Neotope Neuroscience Ltd., a subsidiary of Novo Nordisk A/S, is a company headquartered in Dublin, Ireland. The firm develops novel antibodies. It was founded in 2019. Novo Nordisk An acquired Neotope Neuroscience Ltd. from Prothena Corp. Plc on July 12, 2021 for $1,459.33 million.

Bracco Imaging SpA manufactures and develops diagnostic imaging solutions for public and private hospitals, imaging centers and private practices. The firm's services include radiology, X-ray imaging, magnetic resonance imaging and ultrasound applications. The company was founded in 1985 and is headquartered in Milan, Italy.

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

Metabasis is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs by applying its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' product pipeline represents candidates indicated for the treatment of metabolic diseases such as hyperlipidemia and diabetes, among others. Additionally, our pipeline includes drug candidates for the treatment of liver diseases such as hepatitis and primary liver cancer which the company plans to license to companies focused on these areas. All of our product candidates were developed internally using proprietary technologies including our NuMimetic and HepDirect technologies.

Plex Pharmaceuticals, Inc. operates as a biotechnology company which focuses on the discovery of drug-lie small molecules for underserved needs. Its products are used in the treatment of CNS/systemic, oncology, degenerative, CNS disorders and infectious diseases. The company was founded in 2009 and is headquartered in San Diego, CA.

Berlin-Chemie AG engages in the manufacture of pharmaceutical products. It offers products for therapeutic areas, which include inflammatory diseases and pain; gastroenterology; neurology; diabetes; cardiovascular diseases; oncology; and viral diseases. The company was founded in 1890 and is headquartered in Berlin, Germany.

Suzhou Creus Pharmaceutical Co., Ltd., established on 2015-11-30, The business scope includes research and development of crystal drugs and their preparations,Production and sales of APIs,preparation,Acting API,Import and export business of preparations,And provide raw materials,Preparation analysis and testing services,Technology development in the field of pharmaceuticals,technical consulting,technology transfer,Technical Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Corino Therapeutics, Inc. is a private, development-stage biopharmaceutical company focused on acquiring, developing, and commercializing innovative products for the treatment of a variety of human diseases, particularly orphan indications. Corino develops technologies that address important unmet medical needs, and which offer improved, cost-effective alternatives to current methods of treatment. Preclinical and early clinical data suggests that Corino's lead product candidate, CRX-1008, may provide a safe and effective treatment for all forms of Transthyretin Amyloidosis (ATTR). Having been approved for nearly 20 years, the active compound in CRX-1008 has extensive safety and toxicity data. Further, the compound's efficacy has been demonstrated in the new indication of ATTR.

Kylonova (Xiamen) Biopharma Co., Ltd. is mainly engaged in the research and development of new drugs and delivery platforms for siRNA (small interfering nucleic acids). The company has established three delivery platforms for siRNA with proprietary technologies, including Nano-Lipid Particle(NPDP) , a Multi-Valent Import platform (MVIP) and Lipid-Coupling Delivery platform(LCDP). The technologies and quality standards of three delivery platforms are on the cutting-edge in the same fields, and can be scaled-up and manufactured for commercialization. Kylonova also performssolid phase oligonucleotide synthesis and DNA and RNA API production and can supply a contract manufacture.